Equity Profile

IMVT

Immunovant, Inc.

Health CareBiotechnology$7.9B

Aug10Mon

Pre-Earnings Brief

UpcomingQ1-2027Pre-Market9:00 AM EDT

Company Snapshot

Immunovant, Inc. is a biotechnology company focused on developing therapies for autoimmune diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a critical measure of profitability and will indicate how well the company is managing its costs and generating revenue.

N/A

Revenue Growth

Revenue growth is essential for assessing the company's ability to expand its market presence and support future development.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

IMVT Q1-2027 Earnings Preview

Context

Company Snapshot

Immunovant, Inc. is a biotechnology company focused on developing therapies for autoimmune diseases. With a market cap of $8 billion, it operates in the health care sector, which is increasingly important as the demand for innovative treatments continues to grow.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-3.82%

Avg Stock Reaction

+4.85%

Last Quarter Recap

In the last quarter, Immunovant reported an EPS of -$0.73, missing estimates by 21%. Despite this, the stock rose by over 35% the following day, indicating strong investor interest.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations are mixed as the company has a history of both beating and missing EPS estimates. Investors will be closely watching for any signs of improvement in revenue and clinical trial updates.

Bull Case

If Immunovant can show significant progress in its clinical trials and report better-than-expected EPS, it could lead to a strong rally in the stock price.

Bear Case

Conversely, if the company misses on EPS again and provides no clear guidance on future developments, it may lead to a decline in stock value.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of ongoing clinical trials?

Updates on clinical trials can significantly influence the stock price and investor confidence in the company's future.

How does the company plan to manage costs moving forward?

Cost management will be crucial for improving EPS and overall financial health, especially in a competitive biotech landscape.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating the potential for a turnaround in clinical trial results, which could significantly boost investor sentiment.

Supporting Evidence

The stock has shown resilience in the past despite earnings misses, indicating strong underlying interest.

Options pricing suggests a larger move than historical averages, indicating heightened expectations.

Insider selling may be a short-term strategy rather than a lack of confidence in the company's future.

Key Risk

If the company provides a strong update on clinical trials, it could shift the narrative and lead to a significant stock price increase.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the company's ability to turn around its financial performance and provide clarity on its future growth prospects.

Bull Confirmed If

A positive update on clinical trial results could confirm the bull case, potentially leading to a significant stock price increase.

Bear Confirmed If

A continued trend of EPS misses without clear guidance could confirm the bear case, leading to a decline in investor confidence.

Pre-Earnings Positioning

Options Market

Implied Move

±29.13%

Historical Avg

±9.6%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report.

Options are pricing ±29.1% while IMVT has averaged ±9.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

100.4%

Calls (69K)P/C Ratio: 0.06Puts (6K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Immunovant beats expectations, history suggests an average 1-day move of +4.50%, confirming a positive outlook for the company.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted reaction as investors await further guidance.

Miss

Should the company miss expectations again, history suggests an average 1-day move of +5.06%, indicating potential downside.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of clinical trials and any new data.
2Management's strategy for cost management and future profitability.
3Any guidance on expected revenue growth or new partnerships.
4Insights into competitive positioning within the biotechnology sector.
5Responses to analyst questions regarding recent insider selling.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug7

PAABMO

Plains All American Pipeline, L.P.

PreviewView

Aug7

ESNTBMO

Company Snapshot

Immunovant, Inc. is a biotechnology company focused on developing therapies for autoimmune diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a critical measure of profitability and will indicate how well the company is managing its costs and generating revenue.

N/A

Revenue Growth

Revenue growth is essential for assessing the company's ability to expand its market presence and support future development.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

IMVT Q1-2027 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-3.82%

Avg Stock Reaction

+4.85%

Last Quarter Recap

In the last quarter, Immunovant reported an EPS of -$0.73, missing estimates by 21%. Despite this, the stock rose by over 35% the following day, indicating strong investor interest.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Immunovant can show significant progress in its clinical trials and report better-than-expected EPS, it could lead to a strong rally in the stock price.

Bear Case

Conversely, if the company misses on EPS again and provides no clear guidance on future developments, it may lead to a decline in stock value.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of ongoing clinical trials?

Updates on clinical trials can significantly influence the stock price and investor confidence in the company's future.

How does the company plan to manage costs moving forward?

Cost management will be crucial for improving EPS and overall financial health, especially in a competitive biotech landscape.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating the potential for a turnaround in clinical trial results, which could significantly boost investor sentiment.

Supporting Evidence

The stock has shown resilience in the past despite earnings misses, indicating strong underlying interest.

Options pricing suggests a larger move than historical averages, indicating heightened expectations.

Insider selling may be a short-term strategy rather than a lack of confidence in the company's future.

Key Risk

If the company provides a strong update on clinical trials, it could shift the narrative and lead to a significant stock price increase.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the company's ability to turn around its financial performance and provide clarity on its future growth prospects.

Bull Confirmed If

A positive update on clinical trial results could confirm the bull case, potentially leading to a significant stock price increase.

Bear Confirmed If

A continued trend of EPS misses without clear guidance could confirm the bear case, leading to a decline in investor confidence.

Pre-Earnings Positioning

Options Market

Implied Move

±29.13%

Historical Avg

±9.6%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report.

Options are pricing ±29.1% while IMVT has averaged ±9.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

100.4%

Calls (69K)P/C Ratio: 0.06Puts (6K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Immunovant beats expectations, history suggests an average 1-day move of +4.50%, confirming a positive outlook for the company.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted reaction as investors await further guidance.

Miss

Should the company miss expectations again, history suggests an average 1-day move of +5.06%, indicating potential downside.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of clinical trials and any new data.
2Management's strategy for cost management and future profitability.
3Any guidance on expected revenue growth or new partnerships.
4Insights into competitive positioning within the biotechnology sector.
5Responses to analyst questions regarding recent insider selling.